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Depression is one of the most common mental health 
disorders globally, presenting an increasing burden 
everywhere — as are hypertension-related diseases. 
Depression nearly doubles the risk for developing 
coronary heart disease, and in those already suffering 
from heart disease, depression nearly doubles the 
risk of mortality [1, 2]. This elevated cardiac risk 
associated with depression is independent of classical 
risk factors, and similar in degree to smoking and 
hypercholesterolaemia.
The mechanisms whereby depressive illness can 
trigger atherosclerosis are supposed to be deregu-
lation in the sympathetic nervous system and hy-
pothalamic-pituitary-adrenal axis [3, 4]. This in 
turn has a number of harmful downstream effects, 
including increased heart rate and reduced heart 
rate variability, endothelial dysfunction, vasocon-
striction, production of inflammatory cytokines, 
platelet activation, insulin resistance, and elevated 
risk for development of hypertension and metabolic 
syndrome.
There are many standardized questionnaires to as-
sess depressive symptoms, but the diagnosis requires 
a clinical interview and fulfilment of at least four de-
pressive symptoms. Alternatively to questionnaires, 
a preliminary assessment of depression can be made 
with two core questions: 
•	 Do you feel down, depressed and hopeless? 
•	 Have you lost interest and pleasure in life?
Giving a “yes” answer to either one of these core 
questions may be as effective as using longer screen-
ing instruments [5].
Major depression is more prevalent in people who 
have suffered a major cardiac event; the large Euro-
pean EUROASPIRE Study showed rates with up to 
35% in men and 65% in women [6].
If we look at figures from the community, we 
see rates of depression of 10% in general practice 
clinics [7]. There are two European studies con-
ducted among hypertensive patients in which the 
diagnosis of depression has been made by clinical 
interview — “the state of the art method”. In 
the Norwegian community-based study, the prev-
alence of depression was 6%, while in the hospi-
tal-based study in the Netherlands, the prevalence 
was 11% [8].
Depression may act as a barrier to the adoption 
of healthy lifestyle and to its maintenance. There 
are a  number of behavioural and lifestyle factors 
which are present in depressive patients that can 
increase the chance of developing hypertension and 
cardiovascular disease. These include increased rates 
of smoking, alcohol intake, physical inactivity, and 
obesity [9]. Major depression also predicts poor ad-
herence to medications [10].
It is important to recognize depression in hyper-
tensive subjects and when recognized, to treat it. It 
is not known which of the various antidepressants 
available is the best to lower the risk for cardiovas-
cular events. However, selective serotonin reuptake 
inhibitors can be regarded as the first choice because 
of their good tolerability and safety profile also in the 
cardiac setting. On the contrary, tricyclic antidepres-
sants and monoamine oxidase inhibitors may have 
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toxic cardiac side effects, and these drugs should be 
avoided in those who have comorbid cardiac condi-
tions.
Luckily, a Cochrane review has indicated that 
moderate aerobic exercise in the order of 30 min-
utes five times a week is beneficial in relieving de-
pressive symptoms with similar efficacy to cogni-
tive behavioural therapy [11] — with an apparent 
help to control blood pressure, too.
When prescribing beta-blockers, physicians 
may have concerns about development of depres-
sion. However, this conventional wisdom is not 
supported by randomized trial data. Depression, 
fatigue and sexual dysfunction are common com-
plaints also among placebo treated subjects.
Depression is often invisible, silent, and de-
nied. But it is common in hypertensive subjects. 
The toxic combination of hypertension and de-
pression leads to poor health outcomes for both 
conditions. Depression should be considered as 
a modifiable risk factor for hypertension and car-
diovascular disease — just like we do for smoking, 
and hypercholesterolaemia. Depression should be 
screened at least among uncontrolled hyperten-
sive subjects, and busy clinicians could utilize the 
core questions as a  quick and simple screening 
method for the terrible two — hypertension and 
depression.
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